Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Drugs used in chemotherapy, such as irinotecan and cisplatin,
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill
more tumor cells. Giving imatinib mesylate after irinotecan and cisplatin may keep the tumor
from coming back.
PURPOSE: This phase II trial is studying how well giving imatinib mesylate after irinotecan
and cisplatin works in treating patients with extensive-stage small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Barbara Ann Karmanos Cancer Institute
Collaborators:
National Cancer Institute (NCI) Novartis Pharmaceuticals